Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and
identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with
ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors.